ASMB (Assembly Biosciences) 5-Year EBITDA Growth Rate: 42.20% (As of Mar. 2026)


ASMB Assembly Biosciences Inc ASMB
31 GF Score
Price $27.42
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences 5-Year EBITDA Growth Rate?

Assembly Biosciences ASMB -1.69% 31 5-Year EBITDA Growth Rate is 42.20% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Assembly Biosciences's EBITDA per Share for the three months ended in Mar. 2026 was $-0.67.

During the past 3 years, the average EBITDA Per Share Growth Rate was 64.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 42.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Assembly Biosciences was 64.20% per year. The lowest was -28.90% per year. And the median was 20.80% per year.

Assembly Biosciences  (NAS:ASMB) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Assembly Biosciences 5-Year EBITDA Growth Rate Related Terms

ASMB vs CTNM, PRTA, RGNX: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Assembly Biosciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's 5-Year EBITDA Growth Rate falls into.


ASMB
31GF Score
Assembly Biosciences Inc ASMB
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 42.20% mean?
Assembly Biosciences (ASMB) has a 5-Year EBITDA Growth Rate of 42.20% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Assembly Biosciences and its competitors.
Is Assembly Biosciences' 5-Year EBITDA Growth Rate too high?
Assembly Biosciences' current 5-Year EBITDA Growth Rate is 42.20%. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' 5-Year EBITDA Growth Rate compare to CTNM and PRTA?
Assembly Biosciences' 5-Year EBITDA Growth Rate of 42.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Assembly Biosciences and its competitors. Assembly Biosciences's current 5-Year EBITDA Growth Rate is 42.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current 5-Year EBITDA Growth Rate of 42.20%. The current 5-Year EBITDA Growth Rate is 42.20%. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current 5-Year EBITDA Growth Rate is 42.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for ASMB

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.42
Price